Low-dose-intensity bevacizumab with weekly irinotecan for platinum- and taxanes-resistant epithelial ovarian cancer.

abstract：PURPOSE:RSR13, 2-[4-[2-[(3,5-dimethylphenyl)amino]-2-oxoethyl]phenoxy]-2-methylpropanoic acid monosodium salt, allosterically modifies hemoglobin to increase tumor pO(2), increases the effect of radiation in animal tumor models, and is in phase III clinical trials as an adjuvant to radiotherapy. Cisplatin and carboplat...

journal_title：Cancer chemotherapy and pharmacology

authors： Donnelly ET,Kelley M,Rockwell S

更新日期：2004-01-01 00:00:00

abstract：PURPOSE:Curcumin, a major constituent of the spice turmeric, suppresses expression of the enzyme cyclooxygenase 2 (Cox-2) and has cancer chemopreventive properties in rodents. It possesses poor systemic availability. We explored whether formulation with phosphatidylcholine increases the oral bioavailability or affects ...

journal_title：Cancer chemotherapy and pharmacology

authors： Marczylo TH,Verschoyle RD,Cooke DN,Morazzoni P,Steward WP,Gescher AJ

更新日期：2007-07-01 00:00:00

abstract：PURPOSE:The study investigated the effects of pemetrexed, gefitinib, and their combination on human colorectal cancer cells. METHODS:Six human colorectal cancer cells were exposed to pemetrexed, gefitinib, and their combination. Antitumor effects were measured by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium br...

journal_title：Cancer chemotherapy and pharmacology

authors： Zhang G,Xie X,Liu T,Yang J,Jiao S

更新日期：2013-10-01 00:00:00

abstract：:Tumor angiogenesis is essential for tumor growth and metastasis formation. Luminex methodology was used to measure the levels of four angiogenic cytokines in cell culture medium and in the plasma of mice bearing human tumors. We obtained plasma and conditioned culture medium from 12 different human tumor cell lines. T...

journal_title：Cancer chemotherapy and pharmacology

authors： Keyes KA,Mann L,Cox K,Treadway P,Iversen P,Chen YF,Teicher BA

更新日期：2003-04-01 00:00:00

abstract：PURPOSE:This phase I study assessed the safety, tolerability, maximum tolerated dose (MTD), pharmacokinetics, and preliminary antitumor effects of sunitinib combined with modified FOLFOX6 (mFOLFOX6). METHODS:Patients with advanced solid malignancies received mFOLFOX6 in 2-week cycles with escalating sunitinib doses (2...

journal_title：Cancer chemotherapy and pharmacology

authors： Leong S,Eckhardt SG,Chan E,Messersmith WA,Spratlin J,Camidge DR,Diab S,Khosravan R,Lin X,Chow Maneval E,Lockhart AC

更新日期：2012-07-01 00:00:00

abstract：:CD-1 mice are commonly used in oncology metabolism and toxicity to support drug discovery and development and to examine drug metabolism and toxicity properties of new chemical entities. On the other hand, athymic nude mice are the preferred animals to investigate tumor growth inhibition. Therefore, a frequently asked...

journal_title：Cancer chemotherapy and pharmacology

authors： Martignoni M,de Kanter R,Moscone A,Grossi P,Monshouwer M

更新日期：2005-02-01 00:00:00

abstract：OBJECTIVE:The aim of this study was to evaluate the efficacy and toxicities of liposome-paclitaxel and carboplatin concurrent with radiotherapy for locally advanced lung squamous cell carcinoma (LSCC). METHODS:The clinical data of 38 patients with locally advanced LSCC treated with liposome-paclitaxel based concurrent...

journal_title：Cancer chemotherapy and pharmacology

authors： Chen G,Sheng L,Du X

更新日期：2018-09-01 00:00:00

abstract：:A sensitive solid-phase-extraction and high-performance liquid chromatography (HPLC) method has been developed to investigate the pharmacokinetics and metabolism of the hypoxic-cell cytotoxic agent tirapazamine (1,2,4-benzotriazine-3-amine 1,4-di-N-oxide; WIN 59075, SR 4233), currently in phase I/II studies in the Uni...

journal_title：Cancer chemotherapy and pharmacology

authors： Robin H Jr,Senan S,Workman P,Graham MA

更新日期：1995-01-01 00:00:00

abstract：PURPOSE:Tyrosine kinase inhibitors (TKI) that target MET signaling have shown promise in various types of cancer, including lung cancer. Combination strategies have been proposed and developed to increase their therapeutic index. Based on preclinical synergy between inhibition of MET and topoisomerase I, a phase I stud...

journal_title：Cancer chemotherapy and pharmacology

authors： Liu SV,Groshen SG,Kelly K,Reckamp KL,Belani C,Synold TW,Goldkorn A,Gitlitz BJ,Cristea MC,Gong IY,Semrad TJ,Xu Y,Xu T,Koczywas M,Gandara DR,Newman EM

更新日期：2018-10-01 00:00:00

abstract：:Thirty-two evaluable patients with advanced measurable gastric adenocarcinoma were treated with a combination of 5-fluorouracil, adriamycin, and BCNU (FAB). Two complete and fourteen partial responses were observed, with an overall response rate of 50%. The median duration of response was 10 months, and the median sur...

journal_title：Cancer chemotherapy and pharmacology

authors： Lopez M,Perno CF,Di Lauro L,Papaldo P

更新日期：1984-01-01 00:00:00

abstract：:Leucovorin requirements for protection of the T cell line CCRF-CEM and the B cell line LAZ-007 against the cytotoxic effects of a variety of antifolates were studied. Differential leucovorin protection for DDMP-induced growth suppression occurred in the opposite direction to that for MTX, with CCRF-CEM requiring less ...

journal_title：Cancer chemotherapy and pharmacology

authors： Browman GP,Spiegl P,Booker L,Rosowsky A

更新日期：1985-01-01 00:00:00

abstract：PURPOSE:Pharmacokinetic-pharmacodynamic (PK-PD) models able to predict the action of anticancer compounds in tumor xenografts have an important impact on drug development. In case of anti-angiogenic compounds, many of the available models show difficulties in their applications, as they are based on a cell kill hypothe...

journal_title：Cancer chemotherapy and pharmacology

authors： Rocchetti M,Germani M,Del Bene F,Poggesi I,Magni P,Pesenti E,De Nicolao G

更新日期：2013-05-01 00:00:00

abstract：:Mouse colon adenocarcinoma Co38 is widely used as a screening model for human colon tumors. To understand better the influence of tumor size on the main drug-metabolizing enzyme systems, we tested 15 mouse Co38 tumors at different sizes. The average weight was 917 +/- 444 mg (range, 300-1,400 mg). Cytochromes P-450 (1...

journal_title：Cancer chemotherapy and pharmacology

authors： Massaad L,Chabot GG,Toussaint C,Koscielny S,Morizet J,Bissery MC,Gouyette A

更新日期：1994-01-01 00:00:00

abstract：:The value of estrogen receptor (ER) status in the prediction of tumor response to combination chemotherapy was retrospectively analyzed in breast cancer patients selected for prospective controlled trials of chemotherapy (85 with advanced disease and 256 with operable tumors). All patients were previously untreated wi...

journal_title：Cancer chemotherapy and pharmacology

authors： Bonadonna G,Valagussa P,Tancini G,Di Fronzo G

更新日期：1980-01-01 00:00:00

abstract：PURPOSE:Gemcitabine (2',2'-difluorodeoxycytidine) is an antineoplastic agent with activity against a variety of solid tumors. To investigate its in vitro activity toward cervical cancer, we exposed six cervical cancer cell lines to gemcitabine. METHODS:Combinational cytotoxic studies using viability tests and clonogen...

journal_title：Cancer chemotherapy and pharmacology

authors： Hernández P,Olivera P,Dueñas-Gonzalez A,Pérez-Pastenes MA,Zárate A,Maldonado V,Meléndez-Zajgla J

更新日期：2001-12-01 00:00:00

abstract：PURPOSE:To review the 20 years of experience at M. D. Anderson Cancer Center with a combined-modality approach against inflammatory breast carcinoma. PATIENTS AND METHODS:A total of 178 patients with inflammatory breast carcinoma were treated in the past 20 years at M. D. Anderson Cancer Center by a combined-modality ...

journal_title：Cancer chemotherapy and pharmacology

authors： Ueno NT,Buzdar AU,Singletary SE,Ames FC,McNeese MD,Holmes FA,Theriault RL,Strom EA,Wasaff BJ,Asmar L,Frye D,Hortobagyi GN

更新日期：1997-01-01 00:00:00

abstract：BACKGROUND AND AIMS:oxaliplatin in combination with folinic acid (FA) and infusional 5-fluorouracil (5-FU) has shown significant anti-tumor activity in gastric cancer patients (FOLFOX). Previous studies have shown that gemcitabine (GEM), a new fluorinated anti-metabolite, enhances the individual anti-tumor activity of ...

journal_title：Cancer chemotherapy and pharmacology

authors： Correale P,Fulfaro F,Marsili S,Cicero G,Bajardi E,Intrivici C,Vuolo G,Carli AF,Caraglia M,Del Prete S,Greco E,Gebbia N,Francini G

更新日期：2005-12-01 00:00:00

abstract：:In a phase II study we evaluated the effect and toxicity of a new alkylating agent, PTT-119, in 26 patients with non-Hodgkin's lymphomas (NHL) resistant to or relapsed after other chemotherapy. PTT was scheduled by escalating the dose from 2.0 to 3.3 mg/kg every 3 weeks. Among 21 evaluable patients with NHL, 12 (57%) ...

journal_title：Cancer chemotherapy and pharmacology

authors： Tura S,Mazza P,Gherlinzoni F,Zinzani PL,Poletti G,Visani G,Lemoli RM,Cavo M,Galieni P,Tassi C

更新日期：1989-01-01 00:00:00

abstract：:A 72-year-old male with a lymphoma and obstructive jaundice received 900 mg cyclophosphamide IV as a part of a chemotherapeutic regimen whilst external biliary drainage was in progress. Plasma, urinary, and biliary pharmacokinetics of cyclophosphamide and nitrobenzylpyridine (NBP)-alkylating metabolites were studied. ...

journal_title：Cancer chemotherapy and pharmacology

authors： Dooley JS,James CA,Rogers HJ,Stuart-Harris R

更新日期：1982-01-01 00:00:00

abstract：:We compared the safety and efficacy in mice with peritoneal carcinomatosis of two etoposide formulations: an aqueous solution (Etp-sol) and particles suspended in oil (the addition products of iodine and the ethyl esters of the fatty acids obtained from poppy-seed oil (Lipiodol) or sesame oil; Etp-oil). We also invest...

journal_title：Cancer chemotherapy and pharmacology

authors： Lee JS,Takahashi T,Hagiwara A,Yoneyama C,Itoh M,Sasabe T,Muranishi S,Tashima S

更新日期：1995-01-01 00:00:00

abstract：:A series of halogen analogs of phosphoramide mustard, isophosphoramide mustard, and triphosphoramide mustard, the cytotoxic metabolites of the antitumor drugs cyclophosphamide, ifosfamide, and trofosfamide, respectively, was evaluated in vitro against human tumor cell lines and in vivo against experimental tumors to i...

journal_title：Cancer chemotherapy and pharmacology

authors： Struck RF,Schmid SM,Waud WR

更新日期：1994-01-01 00:00:00

abstract：BACKGROUND:Adjuvant chemotherapy is gaining an increasing role in resectable gastric cancer. Customizing chemotherapy on the basis of chemosensitivity may improve outcome, and putative predictive molecular markers have been mostly evaluated in Asian patients. We profiled key DNA and damage signaling factors and correla...

journal_title：Cancer chemotherapy and pharmacology

authors： De Dosso S,Zanellato E,Nucifora M,Boldorini R,Sonzogni A,Biffi R,Fazio N,Bucci E,Beretta O,Crippa S,Saletti P,Frattini M

更新日期：2013-07-01 00:00:00

abstract：PURPOSE:Decitabine is a nucleoside analog used in the treatment for myelodysplastic syndrome. The compound requires intracellular conversion to its triphosphate to become active. Decitabine triphosphate has, however, never been quantified in peripheral blood mononuclear cells (PBMCs) from patients. METHOD:This article...

journal_title：Cancer chemotherapy and pharmacology

authors： Jansen RS,Rosing H,Wijermans PW,Keizer RJ,Schellens JH,Beijnen JH

更新日期：2012-06-01 00:00:00

abstract：:The initial results from the Children's Cancer Study Group (CCSG) study on vindesine are the subject of this report. Vindesine was shown to be active in the treatment of acute lymphocytic leukemia (ALL) in children in a phase-II clinical trial conducted by the CCSG. A phase-II trial is now in progress. The aim of this...

journal_title：Cancer chemotherapy and pharmacology

authors： Krivit W,Chilcote R,Pyesmany A,Anderson J,Hammond D

更新日期：1979-01-01 00:00:00

abstract：:Unfortunately, the online published article has error in Figure 4. The correct Figure 4 is given here. ...

journal_title：Cancer chemotherapy and pharmacology

authors： Zhang Q,Li XT,Chen Y,Chen JQ,Zhu JY,Meng Y,Wang XQ,Li Y,Geng SS,Xie CF,Wu JS,Zhong CY,Han HY

更新日期：2018-06-01 00:00:00

abstract：PURPOSE:miRNAs are implicated in drug resistance of multiple cancers including non-small cell lung cancer (NSCLC), highlighting the potential of miRNAs as chemoresistance regulators in cancer treatment. This study aims to explore the relationship between miR-181c and chemoresistance of NSCLC cells. METHODS:qRT-PCR was...

journal_title：Cancer chemotherapy and pharmacology

authors： Zhang H,Hu B,Wang Z,Zhang F,Wei H,Li L

更新日期：2017-11-01 00:00:00

abstract：PURPOSE:Based on the preclinical evidence of topoisomerase I (Topo-1) upregulation by mitomycin C(MMC) and decreased NF-kappaB activation by celecoxib, we evaluated combinations of irinotecan/MMC and irinotecan/MMC/celecoxib in patients with advanced solid malignancies. PATIENTS-METHODS:Initially, patients received MM...

journal_title：Cancer chemotherapy and pharmacology

authors： Xu Y,Kolesar JM,Schaaf LJ,Drengler R,Duan W,Otterson G,Shapiro C,Kuhn J,Villalona-Calero MA

更新日期：2009-05-01 00:00:00

abstract：PURPOSE:Phosphatidylinositol (PtdIns) 3-kinase is an important mediator of many cellular functions. The study of PtdIns 3-kinase has been facilitated by the existence of the potent irreversible inhibitor of p110 PtdIns 3-kinase, wortmannin. The purpose of the study was to investigate the relationship between the cell g...

journal_title：Cancer chemotherapy and pharmacology

authors： Lemke LE,Paine-Murrieta GD,Taylor CW,Powis G

更新日期：1999-01-01 00:00:00

abstract：PURPOSE:One of the major problems of cancer chemotherapy is the development of multidrug resistance (MDR) phenotype. Among the numerous mechanisms of MDR, a prominent one is the increased expression of membrane transporter proteins, the action of which leads to decreased intracellular drug concentration and cytotoxicit...

journal_title：Cancer chemotherapy and pharmacology

authors： Dönmez Y,Akhmetova L,İşeri ÖD,Kars MD,Gündüz U

更新日期：2011-04-01 00:00:00

abstract：BACKGROUND:The factors which affect the 6-month continuation of adjuvant chemotherapy with S-1 have not been fully evaluated in pancreatic cancer. The objective of this retrospective study was to clarify the risk factors for the discontinuation of S-1 adjuvant chemotherapy after 6 months of treatment. METHODS:The stud...

journal_title：Cancer chemotherapy and pharmacology

authors： Aoyama T,Katayama Y,Murakawa M,Asari M,Kanazawa A,Higuchi A,Shiozawa M,Kobayashi S,Ueno M,Morimoto M,Ohkawa S,Akaike M,Yamamoto N,Yoshikawa T,Rino Y,Masuda M,Morinaga S

更新日期：2014-12-01 00:00:00